NCT06047548: An ongoing trial by Eli Lilly and Company
This trial is ongoing. It must report results 1 year, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06047548 |
|---|---|
| Title | A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Once Weekly 5 mg and/or Maximum Tolerated Dose Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 20, 2023 |
| Completion date | May 31, 2026 |
| Required reporting date | May 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |